RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Knight Therapeutics Stock

Knight Therapeutics Revenue 2024

Knight Therapeutics Revenue

365.35 M CAD

Ticker

GUD.TO

ISIN

CA4990531069

WKN

A1XE7A

In 2024, Knight Therapeutics's sales reached 365.35 M CAD, a 11.32% difference from the 328.2 M CAD sales recorded in the previous year.

The Knight Therapeutics Revenue history

YEARREVENUE (undefined CAD)GROSS MARGIN (%)
2029e490.9131,10
2028e466.6932,71
2027e436.834,95
2026e403.5237,83
2025e367.3841,55
2024e365.3541,78
2023328.246,51
2022293.5647,03
2021243.4847,40
2020199.540,95
201947.556,63
201812.582,40
20178.681,40
20165.974,58
2015160,00
20140.438163,00

Knight Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Knight Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Knight Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Knight Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Knight Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Knight Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Knight Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Knight Therapeutics’s growth potential.

Knight Therapeutics Revenue, EBIT and net profit per share

DateKnight Therapeutics RevenueKnight Therapeutics EBITKnight Therapeutics Net Income
2029e490.91 M undefined0 undefined32.69 M undefined
2028e466.69 M undefined0 undefined30.65 M undefined
2027e436.8 M undefined0 undefined23.5 M undefined
2026e403.52 M undefined-2.75 M undefined12.22 M undefined
2025e367.38 M undefined17.69 M undefined8.35 M undefined
2024e365.35 M undefined11.01 M undefined-5.09 M undefined
2023328.2 M undefined6.37 M undefined-16.84 M undefined
2022293.56 M undefined-17.06 M undefined-29.89 M undefined
2021243.48 M undefined-12.83 M undefined15.68 M undefined
2020199.5 M undefined-26.3 M undefined42.1 M undefined
201947.5 M undefined-4.7 M undefined14.5 M undefined
201812.5 M undefined-5.8 M undefined24.1 M undefined
20178.6 M undefined-8.9 M undefined17.2 M undefined
20165.9 M undefined-3.9 M undefined18.6 M undefined
20151 M undefined-9.1 M undefined34.2 M undefined
2014400,000 undefined-4.6 M undefined125.9 M undefined

Knight Therapeutics stock margins

The Knight Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Knight Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Knight Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Knight Therapeutics's sales revenue. A higher gross margin percentage indicates that the Knight Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Knight Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Knight Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Knight Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Knight Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Knight Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Knight Therapeutics Margin History

Knight Therapeutics Gross marginKnight Therapeutics Profit marginKnight Therapeutics EBIT marginKnight Therapeutics Profit margin
2029e46.51 %0 %6.66 %
2028e46.51 %0 %6.57 %
2027e46.51 %0 %5.38 %
2026e46.51 %-0.68 %3.03 %
2025e46.51 %4.81 %2.27 %
2024e46.51 %3.01 %-1.39 %
202346.51 %1.94 %-5.13 %
202247.03 %-5.81 %-10.18 %
202147.4 %-5.27 %6.44 %
202040.95 %-13.18 %21.1 %
201956.63 %-9.89 %30.53 %
201882.4 %-46.4 %192.8 %
201781.4 %-103.49 %200 %
201674.58 %-66.1 %315.25 %
201560 %-910 %3,420 %
201446.51 %-1,150 %31,475 %

Knight Therapeutics Aktienanalyse

What does Knight Therapeutics do?

Knight Therapeutics Inc is a Canadian biopharmaceutical company that was founded in 2014. The company is listed on the Toronto Stock Exchange and NASDAQ, making it accessible to all investors. The company's business philosophy is based on the "Acquire and Develop" model, which involves developing acquired products or products that were previously in the approval phase for market testing. Knight Therapeutics focuses on the development and commercialization of pharmaceutical products in Latin America and Canada. The company has gained overseas experience by signing long-term agreements with significant international pharmaceutical companies, including a Japanese and a South Korean pharmaceutical company. In Canada, Knight is in a position to meet the increased demand for innovative drug research and provide patients with important therapies. In Latin America, they focus on achieving broader access to innovative drugs. In this regard, the company is actively working to expand its portfolio of safe, high-quality, and effective medications for this region. The company's product range includes a wide range of priority pharmaceutical areas such as cancer treatments, eye diseases, cardiology, infectious diseases, and pain relief. The company has the expertise to manufacture and distribute specialized treatment options for many diseases, such as cancer and rare diseases. One of Knight Therapeutics' most well-known products is the drug Probuphine. It was approved by the US Food and Drug Administration in May 2016 to help patients with opioid dependence. Knight acquired the product under license from the manufacturer Braeburn Pharmaceuticals. Permian LLC, a real estate fund specializing in retail properties, attempted to acquire Knight with a $150 per share offer. However, this deal was rejected due to Knight's stock dilutions. Another important product of the company is Neuragen, which is used for neuropathic pain and fibromyalgia. It is currently approved in Canada and Brazil, but approvals in the US and other countries are also being sought. Furthermore, Knight Therapeutics is also involved in the manufacturing of generic narcotics and has already concluded some potentially profitable contracts to introduce these products into the Latin American pharmaceutical market. The company has also signed an extremely promising agreement with SAI Life Sciences to develop compounds for the treatment of pain and inflammation. Knight Therapeutics' roadmap also includes a strong partnership with Canadian company Triumvira Immunologics for the further development of cancer treatments, as well as a collaboration with Endoceutics to introduce Prasterone, a superior treatment for vaginal atrophy, menopausal symptoms, and hot flashes in women, to increase bone density and improve sexual life. Overall, Knight Therapeutics has a solid reputation as an emerging player in the pharmaceutical market and is known for its advanced research and development of drugs, with a particular focus on oncology, ophthalmology, and cardiology. It remains to be seen how the company will develop in the future, but it appears that with the aggressive development of innovative products and the expansion into new markets, Knight has great potential to increase its market share in the pharmaceutical industry as a whole. Knight Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Knight Therapeutics's Sales Figures

The sales figures of Knight Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Knight Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Knight Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Knight Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Knight Therapeutics stock

How much revenue did Knight Therapeutics generate this year?

Knight Therapeutics has achieved a revenue of 365.35 M CAD this year.

How much was the turnover of the company Knight Therapeutics compared to the previous year?

The revenue of Knight Therapeutics has increased by 11.32% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Knight Therapeutics?

The revenue of Knight Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Knight Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Knight Therapeutics so important for investors?

The revenue of Knight Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Knight Therapeutics pay?

Over the past 12 months, Knight Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Knight Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Knight Therapeutics?

The current dividend yield of Knight Therapeutics is .

When does Knight Therapeutics pay dividends?

Knight Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Knight Therapeutics?

Knight Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Knight Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Knight Therapeutics located?

Knight Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Knight Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Knight Therapeutics from 12/2/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 12/2/2024.

When did Knight Therapeutics pay the last dividend?

The last dividend was paid out on 12/2/2024.

What was the dividend of Knight Therapeutics in the year 2023?

In the year 2023, Knight Therapeutics distributed 0 CAD as dividends.

In which currency does Knight Therapeutics pay out the dividend?

The dividends of Knight Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Knight Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Knight Therapeutics

Our stock analysis for Knight Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Knight Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.